Summary

According to our latest study on "Neuromodulation Devices Market Forecast to 2030 – Global and Regional Share, Trend, and Growth Opportunity Analysis – by Type, Application, Biomaterial, and End User," the market was valued at US$ 5.73 billion in 2022 and is expected to reach US$ 11.61 billion by 2030; it is estimated to register a CAGR of 9.2% from 2022 to 2030.

Neuromodulation devices are advanced medical instruments that can adjust the activity of the nervous system. The technology is used to treat movement disorders such as dystonia, Parkinson’s disease, and tremor; tinnitus; obsessive-compulsive disorder; sensory disabilities; epilepsy; bladder control; headache; chronic pain; stroke; minimally conscious state; spasticity; and spinal cord injury.

According to the WHO, in 2022, the US recorded 50 million epilepsy cases, 1 billion migraine cases, and 400,000 spinal cord injury cases. Spinal cord stimulation is one of the most preferred techniques in treating chronic back pain, primarily due to the anatomical and functional abilities of the spinal cord nerves to control the sensation of pain. The incidence of spinal cord injuries has grown over the past decade. The National Spinal Cord Injury Statistical Center (NSCISC) 2021 fact sheet states that the annual incidence of spinal cord injuries is 60 cases per million. According to the article titled "Epidemiology of traumatic spinal cord injuries: a large population-based study," published in April 2022, the overall age-sex standardized incidence rate of traumatic spinal cord injuries was 26.5 per 1 million population, and the rates were related to age in both sexes. According to the same source, in elderly (≥ 65 years) population, the rate is 59.2 and 23.3 per 1 million in males and females, respectively. Spinal cord stimulators can be useful in managing postoperative pain associated with spinal surgery. An increase in number of spinal cord surgeries propels the demand for spinal cord stimulators. Therefore, high incidence of spinal cord injuries in old age and adults stimulates the demand for neuromodulation devices.

By Application, Neuromodulation Devices Market-Based Insights

The neuromodulation devices market, by application, is segmented into deep brain stimulation (DBS), sacral nerve stimulation (SNS), gastric electrical stimulation (GES), spinal cord stimulation (SCS), and vagus nerve stimulation (VNS). The spinal cord stimulation segment held the largest market share in 2022 and is expected to record the highest CAGR in the market during 2022–2030. Spinal cord stimulation has been used for years and is advised for a growing number of conditions. Cervical and lumbar radiculitis, failed back surgery syndrome, complex regional pain syndrome, and neuropathy are a few conditions that the therapy can assist. Spinal cord stimulation is efficacious, safe, and cost effective in chronic pain management. Newer spinal cord stimulation technologies are expanding clinical indications such as visceral and ischemic pain, with potential for further improved efficacy.

By Biomaterial, Neuromodulation Devices Market -Based Insights

Based on biomaterial, the neuromodulation devices market is segmented into metallic, polymeric, and ceramic. In 2022, the metallic segment dominated the market share. However, the polymeric segment is likely to register the highest CAGR during 2022–2030. In neuromodulation devices, metallic biomaterials are frequently utilized, especially in electrodes and other parts that need to be highly durable and electrically conductive. Owing to their great strength-to-weight ratio and exceptional biocompatibility, titanium and its alloys are frequently used in neuromodulation devices.

Center for Disease Control and Prevention, and Brazilian Institute of Neuroscience and Neurotechnology are a few of the major primary and secondary sources referred to while preparing the report on the neuromodulation devices market.

ページTOPに戻る

Table of Contents

1. Introduction
1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness Analysis
3. Research Methodology
4. Neuromodulation Devices Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
4.3.1 List of Vendors in the Value Chain
5. Neuromodulation Devices Market - Key Market Dynamics
5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints
6. Neuromodulation Devices Market - Global Market Analysis
6.1 Neuromodulation Devices - Global Market Overview
6.2 Neuromodulation Devices - Global Market and Forecast to 2030
7. Neuromodulation Devices Market – Revenue Analysis (USD Million) – By Type, 2020-2030
7.1 Overview
7.2 Internal
7.3 External
8. Neuromodulation Devices Market – Revenue Analysis (USD Million) – By Application, 2020-2030
8.1 Overview
8.2 Deep Brain Stimulation (DBS)
8.3 Gastric Electrical Stimulation (GES)
8.4 Spinal Cord Stimulation (SCS)
8.5 Vagus Nerve Stimulation (VNS)
8.6 Sacral Nerve Stimulation (SNS)
9. Neuromodulation Devices Market – Revenue Analysis (USD Million) – By Biomaterial, 2020-2030
9.1 Overview
9.2 Metallic
9.3 Polymeric
9.4 Ceramic
10. Neuromodulation Devices Market – Revenue Analysis (USD Million) – By End User, 2020-2030
10.1 Overview
10.2 Hospitals
10.3 Clinics
10.4 Home Healthcare
11. Neuromodulation Devices Market - Revenue Analysis (USD Million), 2020-2030 – Geographical Analysis
11.1 North America
11.1.1 North America Neuromodulation Devices Market Overview
11.1.2 North America Neuromodulation Devices Market Revenue and Forecasts to 2030
11.1.3 North America Neuromodulation Devices Market Revenue and Forecasts and Analysis - By Type
11.1.4 North America Neuromodulation Devices Market Revenue and Forecasts and Analysis - By Application
11.1.5 North America Neuromodulation Devices Market Revenue and Forecasts and Analysis - By Biomaterial
11.1.6 North America Neuromodulation Devices Market Revenue and Forecasts and Analysis - By End User
11.1.7 North America Neuromodulation Devices Market Revenue and Forecasts and Analysis - By Countries
11.1.7.1 United States Neuromodulation Devices Market
11.1.7.1.1 United States Neuromodulation Devices Market, by Type
11.1.7.1.2 United States Neuromodulation Devices Market, by Application
11.1.7.1.3 United States Neuromodulation Devices Market, by Biomaterial
11.1.7.1.4 United States Neuromodulation Devices Market, by End User
11.1.7.2 Canada Neuromodulation Devices Market
11.1.7.2.1 Canada Neuromodulation Devices Market, by Type
11.1.7.2.2 Canada Neuromodulation Devices Market, by Application
11.1.7.2.3 Canada Neuromodulation Devices Market, by Biomaterial
11.1.7.2.4 Canada Neuromodulation Devices Market, by End User
11.1.7.3 Mexico Neuromodulation Devices Market
11.1.7.3.1 Mexico Neuromodulation Devices Market, by Type
11.1.7.3.2 Mexico Neuromodulation Devices Market, by Application
11.1.7.3.3 Mexico Neuromodulation Devices Market, by Biomaterial
11.1.7.3.4 Mexico Neuromodulation Devices Market, by End User
Note - Similar analysis would be provided for below mentioned regions/countries

11.2 Europe
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 Spain
11.2.5 United Kingdom
11.2.6 Rest of Europe
11.3 Asia-Pacific
11.3.1 Australia
11.3.2 China
11.3.3 India
11.3.4 Japan
11.3.5 South Korea
11.3.6 Rest of Asia-Pacific
11.4 Middle East and Africa
11.4.1 South Africa
11.4.2 Saudi Arabia
11.4.3 U.A.E
11.4.4 Rest of Middle East and Africa
11.5 South and Central America
11.5.1 Brazil
11.5.2 Argentina
11.5.3 Rest of South and Central America
12. Industry Landscape
12.1 Mergers and Acquisitions
12.2 Agreements, Collaborations, Joint Ventures
12.3 New Product Launches
12.4 Expansions and Other Strategic Developments
13. Competitive Landscape
13.1 Heat Map Analysis by Key Players
13.2 Company Positioning and Concentration
14. Neuromodulation Devices Market - Key Company Profiles
14.1 Boston Scientific Corporation
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
Note - Similar information would be provided for below list of companies

14.2 Abbott
14.3 LivaNova PLC
14.4 Nevro Corp
14.5 NeuroPace, Inc.
14.6 NeuroSigma, Inc.
14.7 Synapse Biomedical Inc.
14.8 Aleva Neurotherapetics SA
14.9 Bioventus
14.10 EnteroMedics Inc
15. Appendix
15.1 Glossary
15.2 About The Insight Partners
15.3 Market Intelligence Cloud